TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health System Intervention to Improve Communication About End-of-Life Care for Vulnerable Patients
Brief Summary: The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting. We are testing a new way to help patients share their preferences for talking about end-of-life care with their clinicians and families. To do this we created a simple, short feedback form. The form is designed to help clinicians understand what patients would like to talk about. The goal of this research study is to show that using a feedback form is possible and can be helpful for patients and their families.


Options:
A: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness | Arm Label: Comparison/Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication Feedback Form for Patients with Serious Illness; Assigned to Arm(s): Feedback Group
B: Arm Label: CBT no choice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: CBT choice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: sertraline no choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: sertraline choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): sertraline choice, sertraline no choice | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT choice, CBT no choice
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: A web based-Patient Decision Aid (PtDA) (shown on the computer) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care. | Intervention Type: OTHER; Name: A web based-Patient Decision Aid (PtDA) (shown on the computer); Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.; Assigned to Arm(s): Control group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse case management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Nurse case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health System Intervention to Improve Communication About End-of-Life Care for Vulnerable Patients
Brief Summary: The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting. We are testing a new way to help patients share their preferences for talking about end-of-life care with their clinicians and families. To do this we created a simple, short feedback form. The form is designed to help clinicians understand what patients would like to talk about. The goal of this research study is to show that using a feedback form is possible and can be helpful for patients and their families.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Audit and Feedback | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Audit and Feedback; Assigned to Arm(s): Intervention
B: Arm Label: Clinicians with MI coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Wait-list control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list control | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Clinicians with MI coaching | Intervention Type: BEHAVIORAL; Name: Wait-list control; Assigned to Arm(s): Wait-list control
C: Arm Label: Early Palliative Care; Type: EXPERIMENTAL; Interventions: Other: early palliative care | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: early palliative care; Assigned to Arm(s): Early Palliative Care
D: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness | Arm Label: Comparison/Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication Feedback Form for Patients with Serious Illness; Assigned to Arm(s): Feedback Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health System Intervention to Improve Communication About End-of-Life Care for Vulnerable Patients
Brief Summary: The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting. We are testing a new way to help patients share their preferences for talking about end-of-life care with their clinicians and families. To do this we created a simple, short feedback form. The form is designed to help clinicians understand what patients would like to talk about. The goal of this research study is to show that using a feedback form is possible and can be helpful for patients and their families.


Options:
A: Arm Label: Postal Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Arm Label: Online Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Arm Label: Face-to-face Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Arm Label: Telephone Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Intervention Type: OTHER; Name: 15 Patient Reported Health Status Questions; Assigned to Arm(s): Face-to-face Questionnaire, Online Questionnaire, Postal Questionnaire, Telephone Questionnaire
B: Arm Label: Structured patient visits; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Arm Label: Treatment as usual; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Intervention Type: BEHAVIORAL; Name: Structured patient-centered follow up of depression; Assigned to Arm(s): Structured patient visits, Treatment as usual
C: Arm Label: PCI Group; Type: OTHER; Interventions: Other: Patient Concerns Inventory | Arm Label: Non PCI Group; Type: OTHER; Interventions: Other: No Patient Concerns Inventory | Intervention Type: OTHER; Name: Patient Concerns Inventory; Assigned to Arm(s): PCI Group | Intervention Type: OTHER; Name: No Patient Concerns Inventory; Assigned to Arm(s): Non PCI Group
D: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness | Arm Label: Comparison/Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication Feedback Form for Patients with Serious Illness; Assigned to Arm(s): Feedback Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)
Brief Summary: The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder (ADHD).


Options:
A: Arm Label: Methylphenidate transdermal system; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate transdermal system
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): 1
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Quillivant Oral Suspension XR, Drug: Placebo | Arm Label: Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Quillivant Oral Suspension XR; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Comparator
D: Arm Label: OROS-MPH Group; Type: EXPERIMENTAL; Interventions: Drug: Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH) | Arm Label: Normal Group; Type: ACTIVE_COMPARATOR; Interventions: Other: No intervention | Intervention Type: DRUG; Name: Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH); Assigned to Arm(s): OROS-MPH Group | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Normal Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Multicenter Randomized Controlled Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis
Brief Summary: Enterocolitis(EC) is the most common and serious postoperative complication of Hirschsprung's disease(HD) with high morbidity and mortality. Probiotics are live microbes that, when administered in adequate amounts, confer health benefit to the host.Based on this previous knowledge on the beneficial effects of probiotics during pro-inflammatory conditions of the gastrointestinal tract, investigators hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung's disease associated enterocolitis(HAEC).Investigators conducted a prospective, multicenter, randomized and controlled trial to assess whether oral probiotics could decrease the incidence and severity of Hirschsprung's disease associated enterocolitis(HAEC).


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
B: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Drug: Bifico | Intervention Type: DRUG; Name: Bifico; Assigned to Arm(s): Probiotics
C: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Applicability and Outcome of Regular Exercise Training After Transcatheter Aortic Valve Implantation
Brief Summary: This pilot study will evaluate the effect of a rehabilitative exercise training on exercise capacity in patients after percutaneous aortic valve replacement. It will additionally evaluate the safety of such an approach and the effect on life quality. We hypothesize that regular structured exercise improves exercise capacity in these patients beyond the sole effect of the valve procedure.


Options:
A: Arm Label: Cardiac Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Cardiac Rehabilitation | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cardiac Rehabilitation; Assigned to Arm(s): Cardiac Rehabilitation
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Medtronic Transcatheter Aortic Valve Replacement Systems; Type: EXPERIMENTAL; Interventions: Device: Medtronic Transcatheter Aortic Valve Replacement Systems | Arm Label: Surgical Aortic Valve Replacement (SAVR); Type: ACTIVE_COMPARATOR; Interventions: Device: Surgical Aortic Valve Replacement (SAVR) | Intervention Type: DEVICE; Name: Medtronic Transcatheter Aortic Valve Replacement Systems; Assigned to Arm(s): Medtronic Transcatheter Aortic Valve Replacement Systems | Intervention Type: DEVICE; Name: Surgical Aortic Valve Replacement (SAVR); Assigned to Arm(s): Surgical Aortic Valve Replacement (SAVR)
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Integrated rehabilitation | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated rehabilitation; Assigned to Arm(s): Intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation
Brief Summary: Optimal anticoagulation using heparin with close attention to maintain therapeutic dosing during the procedure is important.

Randomized comparison of continuous and intermittent heparin infusion during catheter ablation of Atrial Fibrillation.


Options:
A: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
B: Arm Label: Continuous heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuous heparin infusion | Arm Label: Intermittent heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent heparin infusion | Intervention Type: DRUG; Name: Continuous heparin infusion; Assigned to Arm(s): Continuous heparin infusion group | Intervention Type: DRUG; Name: Intermittent heparin infusion; Assigned to Arm(s): Intermittent heparin infusion group
C: Arm Label: Bridging anti-coagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin or unfractionated heparin | Arm Label: Continued oral anti-coagulation; Type: EXPERIMENTAL; Interventions: Drug: Warfarin or coumadin | Intervention Type: DRUG; Name: low molecular weight heparin or unfractionated heparin; Assigned to Arm(s): Bridging anti-coagulation | Intervention Type: DRUG; Name: Warfarin or coumadin; Assigned to Arm(s): Continued oral anti-coagulation
D: Arm Label: Standard medical therapy group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Catheter ablation group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter ablation | Intervention Type: PROCEDURE; Name: Catheter ablation; Assigned to Arm(s): Catheter ablation group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanochemical Endovenous Ablation (MOCA) Versus RADiofrequeNcy Ablation (RFA) in the Treatment of Primary Great Saphenous Varicose Veins: a Multicentre Randomized Trial
Brief Summary: The newly developed Mechanochemical Endovenous Ablation (MOCA) device uses a technique that combines mechanical endothelial damage using a rotating wire with the infusion of a liquid sclerosant. Heating of the vein and tumescent anesthesia are not required; only local anesthesia is utilized at the insertion site. Previously we showed that endovenous MOCA, using polidocanol, is feasible and safe in the treatment of great spahenous vein (GSV) incompetence. However, larger studies with a prolonged follow-up to prove the efficacy of this technique in terms of obliteration rates are lacking. This randomized trial was designed to compare occlusion rate, post-operative pain and complications between radiofrequency ablation (RFA: the current treatment for GSV incompetence) en MOCA.


Options:
A: Arm Label: MOCA; Type: EXPERIMENTAL; Interventions: Procedure: MOCA | Arm Label: EVLA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EVLA | Arm Label: RFA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RFA | Intervention Type: PROCEDURE; Name: MOCA; Assigned to Arm(s): MOCA | Intervention Type: PROCEDURE; Name: EVLA; Assigned to Arm(s): EVLA | Intervention Type: PROCEDURE; Name: RFA; Assigned to Arm(s): RFA
B: Arm Label: High ligation and stripping (surgery); Type: N/A; Interventions: N/A | Arm Label: Foam sclerotherapy; Type: N/A; Interventions: N/A
C: Arm Label: RFA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency ablation (RFA) | Arm Label: MOCA; Type: EXPERIMENTAL; Interventions: Device: Mechanochemical Endovenous Ablation (MOCA) | Intervention Type: DEVICE; Name: Mechanochemical Endovenous Ablation (MOCA); Assigned to Arm(s): MOCA | Intervention Type: PROCEDURE; Name: Radiofrequency ablation (RFA); Assigned to Arm(s): RFA
D: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery - Saphenofemoral ligation, saphenous strip and avulsions | Arm Label: EVLT; Type: EXPERIMENTAL; Interventions: Procedure: EVLT | Intervention Type: PROCEDURE; Name: Surgery - Saphenofemoral ligation, saphenous strip and avulsions; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: EVLT; Assigned to Arm(s): EVLT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Infarction Genes (MI-GENES) Study - Using Genomic Data to Refine Risk Assessment for Heart Attack
Brief Summary: This study is being done to better understand how genetic information might improve assessment of heart attack risk.


Options:
A: Arm Label: Population Health Management Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Population Health Management Intervention | Arm Label: Usual Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Population Health Management Intervention; Assigned to Arm(s): Population Health Management Intervention
B: Arm Label: Framingham Risk Score; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Framingham and Genetic Risk Score; Type: ACTIVE_COMPARATOR; Interventions: Other: Genetic Risk Score | Intervention Type: OTHER; Name: Genetic Risk Score; Assigned to Arm(s): Framingham and Genetic Risk Score
C: Arm Label: Control (Usual Care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Simplified cardiovascular disease management | Intervention Type: OTHER; Name: Simplified cardiovascular disease management; Assigned to Arm(s): Intervention
D: Arm Label: Absolute risk reduction information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Absolute risk reduction | Arm Label: Prolongation of life information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolongation of life | Intervention Type: BEHAVIORAL; Name: Absolute risk reduction; Assigned to Arm(s): Absolute risk reduction information | Intervention Type: BEHAVIORAL; Name: Prolongation of life; Assigned to Arm(s): Prolongation of life information

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Infarction Genes (MI-GENES) Study - Using Genomic Data to Refine Risk Assessment for Heart Attack
Brief Summary: This study is being done to better understand how genetic information might improve assessment of heart attack risk.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training and coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication training and coaching; Assigned to Arm(s): Intervention
B: Arm Label: Framingham Risk Score; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Framingham and Genetic Risk Score; Type: ACTIVE_COMPARATOR; Interventions: Other: Genetic Risk Score | Intervention Type: OTHER; Name: Genetic Risk Score; Assigned to Arm(s): Framingham and Genetic Risk Score
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: MyHealthyChoices | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health Risk Assessment | Intervention Type: BEHAVIORAL; Name: MyHealthyChoices; Assigned to Arm(s): Intervention Group | Intervention Type: OTHER; Name: Health Risk Assessment; Assigned to Arm(s): Control Group
D: Arm Label: Absolute risk reduction information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Absolute risk reduction | Arm Label: Prolongation of life information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolongation of life | Intervention Type: BEHAVIORAL; Name: Absolute risk reduction; Assigned to Arm(s): Absolute risk reduction information | Intervention Type: BEHAVIORAL; Name: Prolongation of life; Assigned to Arm(s): Prolongation of life information

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Crossover Trial to Assess the Effects of Dairy Intake on Insulin Sensitivity and β-Cell Function in Men and Women at Risk for Diabetes Who Are Habitual Consumers of High Sugar Beverages
Brief Summary: The aim of this trial is to evaluate the effects of dairy product consumption on insulin sensitivity and pancreatic β-cell function in men and women at risk for the development of type 2 diabetes mellitus (T2DM) who habitually consume beverages high in sugar (non-diet sodas and fruit juice cocktails).


Options:
A: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group
B: Arm Label: Sucrose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sucrose | Arm Label: Aspartame; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Aspartame | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DIETARY_SUPPLEMENT; Name: Aspartame; Assigned to Arm(s): Aspartame
C: Arm Label: Fructose 9%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Arm Label: Glucose 9%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Arm Label: High fructose corn syrup 18%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Arm Label: Sucrose 18%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Intervention Type: BEHAVIORAL; Name: Dietary Compliance; Assigned to Arm(s): Fructose 9%, Glucose 9%, High fructose corn syrup 18%, Sucrose 18%
D: Arm Label: Low-fat dairy; Type: EXPERIMENTAL; Interventions: Other: Low-fat dairy | Arm Label: Sugar-sweetened beverages; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar-sweetened beverages | Intervention Type: OTHER; Name: Low-fat dairy; Assigned to Arm(s): Low-fat dairy | Intervention Type: OTHER; Name: Sugar-sweetened beverages; Assigned to Arm(s): Sugar-sweetened beverages

Answer: D